LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

22.8 1.33

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.16

Máximo

23.8

Métricas clave
By Trading Economics
Ingresos	152M 242M
Ventas	10M 118M
P/B Media del Sector	7.009 49.8
Margen de beneficios	204.74
Empleados	159
EBITDA	100M 208M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+53.64% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	43M 1.7B
Apertura anterior	21.47
Cierre anterior	22.8

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

78 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

18.57 / 18.75 Soporte y Resistencia

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 may 2026, 23:58 UTC

Ganancias

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 may 2026, 22:57 UTC

Ganancias

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 may 2026, 23:52 UTC

Ganancias

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 may 2026, 23:28 UTC

Charlas de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 may 2026, 23:11 UTC

Ganancias

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 may 2026, 23:06 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 may 2026, 23:05 UTC

Ganancias

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 may 2026, 23:04 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 may 2026, 23:03 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 may 2026, 23:03 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 may 2026, 23:02 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 may 2026, 23:00 UTC

Charlas de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 may 2026, 22:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 may 2026, 22:45 UTC

Charlas de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 may 2026, 22:42 UTC

Ganancias

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 may 2026, 22:33 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 may 2026, 22:32 UTC

Ganancias

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 may 2026, 22:31 UTC

Ganancias

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 may 2026, 22:31 UTC

Ganancias

Macquarie: 68% of FY Income From International >MQG.AU

7 may 2026, 22:30 UTC

Ganancias

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 may 2026, 22:30 UTC

Ganancias

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 may 2026, 22:29 UTC

Ganancias

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 may 2026, 22:28 UTC

Ganancias

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 may 2026, 22:28 UTC

Ganancias

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 may 2026, 22:27 UTC

Ganancias

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 may 2026, 22:27 UTC

Ganancias

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 may 2026, 22:26 UTC

Ganancias

Macquarie to End Share Buyback Extended in November>MQG.AU

7 may 2026, 22:25 UTC

Ganancias

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

53.64% repunte

Estimación a 12 Meses

Media 34.6 USD 53.64%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

78 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.